<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Posts on Bruce C. Xu</title><link>https://brucechanglongxu.github.io/posts/</link><description>Recent content in Posts on Bruce C. Xu</description><generator>Hugo</generator><language>en-us</language><managingEditor>you@example.com (Bruce Changlong Xu)</managingEditor><webMaster>you@example.com (Bruce Changlong Xu)</webMaster><lastBuildDate>Thu, 28 Aug 2025 00:00:00 +0000</lastBuildDate><atom:link href="https://brucechanglongxu.github.io/posts/index.xml" rel="self" type="application/rss+xml"/><item><title>Towards Oncological Superintelligence</title><link>https://brucechanglongxu.github.io/posts/towards-oncological-superintelligence/</link><pubDate>Thu, 28 Aug 2025 00:00:00 +0000</pubDate><author>you@example.com (Bruce Changlong Xu)</author><guid>https://brucechanglongxu.github.io/posts/towards-oncological-superintelligence/</guid><description>&lt;p&gt;Cancer has always been a disease of time. Time until the BCR-ABL translocation is recognized in a patientâ€™s marrow; time until sequencing reveals a KRAS mutation in a pancreatic biopsy; time until MYC amplification is confirmed in a lymphoma panel. Time until a therapy is chosen, and then time bought by treatments that stretch survival by months when decades are needed. For patients and families, each interval is both hope and dread. For clinicians, it is the weight of complexity and uncertainty pressed into every decision.&lt;/p&gt;</description></item></channel></rss>